Does Anemia Cause QT Prolongation in Patients with Hematologic Disorders?

Medicines and QT Prolongation

"QT clock" to improve detection of QT prolongation in long QT syndrome patients.

BACKGROUND The QT interval is a risk marker for cardiac events such as torsades de pointes. However, QT measurements obtained from a 12-lead ECG during clinic hours may not capture the full extent of a patient's daily QT range. OBJECTIVE The purpose of this study was to evaluate the utility of 24-hour Holter ECG recording in patients with long QT syndrome (LQTS) to identify dynamic changes in...

Drug induced QT prolongation.

The drug-induced QT prolongation predisposes to development of torsades de pointes (TdP) ventricular tachycardia and sudden death. The association between specific drug and development of TdP is difficult to document, therefore, QT prolongation is considered as a surrogate marker of the proarrhythmia risk. Most of the drugs prolong QT interval usually by blocking the potassium IKr current or al...

A family with heritable electrocardiographic QT-prolongation.

A report is presented concerning a family with heritable electrocardiographic QT-prolongation attacks of syncope and possible sudden death. In 23 family members investigated, nine living cases were found to have the anomaly. Of these nine patients at least two had had syncopes in early childhood. Hearing loss was found in three of the nine patients, but in one ofthem this could have been due to...

Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders.

We have used recombinant human erythropoietin (rHuEPO) in a phase 1/11 clinical trial to evaluate its ability to reverse refractory anemia in hematologic disorders. rHuEPO was administered subcutaneously 5 days per week at escalating doses (50 t o 150 U/kg per day). The aim of treatment was a hemoglobin (Hb) level 2 10 g/dL without blood transfusion. Of 25 patients treated, 17 were evaluable, m...